Gedatolisib
Sign in to save this workspacePrimary targets: PI3K, MTOR_FRAP1 · FDA status: Phase III FDA Trials
Selectivity scorecard
KISS
99.75
Gini
0.611
CATDS
0.044
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Gedatolisib. Strongest target: MTOR_FRAP1 at 95.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | MTOR_FRAP1 | 95.0% | 5.0% |
| 2 | DNA_PK | 73.5% | 26.5% |
| 3 | BRAF | 56.5% | 43.5% |
| 4 | TAOK2_TAO1 | 48.6% | 51.4% |
| 5 | RAF1 | 34.9% | 65.1% |
| 6 | ARAF | 31.9% | 68.1% |
| 7 | EIF2AK2 | 23.8% | 76.2% |
| 8 | CK1EPSILON | 21.0% | 79.0% |
| 9 | MYO3B | 20.3% | 79.7% |
| 10 | NEK9 | 19.0% | 81.0% |
| 11 | CK1G1 | 18.1% | 81.9% |
| 12 | LOK_STK10 | 18.0% | 82.0% |
| 13 | PKCB1 | 17.6% | 82.4% |
| 14 | SNRK | 17.0% | 83.0% |
| 15 | CDK9_CYCLIN_T2 | 16.4% | 83.6% |
| 16 | RIPK5 | 16.3% | 83.7% |
| 17 | SLK_STK2 | 15.6% | 84.4% |
| 18 | LATS2 | 15.6% | 84.4% |
| 19 | TAOK1 | 15.5% | 84.5% |
| 20 | DMPK2 | 15.4% | 84.6% |
Selectivity landscape
Where Gedatolisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Gedatolisib.
Annotations
Sign in to read and post annotations.
Loading…